Navigation Links
BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
Date:9/22/2008


Toronto Stock Exchange Symbol: MS

- US$10 million received based on the positive review of interim

analysis for international pivotal multiple sclerosis trial -

EDMONTON, Sept. 22 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that it has received the US$10 million milestone payment from its partner, Eli Lilly and Company.

The milestone payment is based on the previously announced positive review of the scheduled interim analysis of the Company's pivotal phase II/III Canadian and European trial (MAESTRO-01) of dirucotide (MBP8298) in patients with secondary progressive MS. The independent Data Safety Monitoring Board (DSMB) for the MAESTRO-01 trial recommended that the trial proceed to completion based on the interim analysis which included efficacy and safety data from the first 200 patients to complete the trial.

To date, BioMS has received a total of US$97 million in payments from Eli Lilly and Company, based on the licensing and development agreement for dirucotide (MBP8298). An additional $400 million in milestone payments are possible under the terms of the licensing agreement, in addition to escalating royalties on sales.

"We are pleased that our partner has recognized the outcome of the interim analysis as a significant positive event," said Kevin Giese, President and CEO of BioMS Medical. "We look forward to completing the MAESTRO-01 trial and reviewing the complete data set in the second half of 2009."

About BioMS Medical Corp.

-------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide (MBP8298), is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medical to present at Sachs Associates Biotech in Europe Forum
2. BioMS Medical to present at UBS Global Life Sciences Conference
3. BioMS Medicals lead drug, dirucotide (MBP8298) for the treatment of multiple sclerosis, receives fast track designation from FDA
4. BioMS Medical announces its intention to renew a normal course issuer bid
5. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
6. BioMS Medical Announces Second Quarter 2008 Results
7. BioMS Medical completes patient recruitment in phase III U.S. multiple sclerosis trial
8. BioMS Medical to present at BMO Healthcare Conference
9. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
10. BioMS Medical to present at Jefferies Healthcare Conference
11. BioMS Medical to present at 2008 BIO International Convention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014 DNA vaccine pioneer Immunomic ... development of JRC-LAMP-vax, an innovative and safe potential treatment ... studies began this month in Hawaii, moving the world ... The Japanese red cedar releases pollen that causes devastating ... Cedar pollen wreaks similar havoc in Colorado, New Mexico ...
(Date:8/21/2014)... Emmetsburg, IA (PRWEB) August 21, 2014 ... Project LIBERTY Opening , The Court of His Majesty ... King will attend the Grand Opening of POET-DSM Advanced ... on Wednesday, Sept. 3. , The King will take ... formal opening activity, scheduled for 11 a.m.-12:20 p.m. and ...
(Date:8/21/2014)... 21, 2014 OTC Markets Group ... a biotechnology company, on its approval to list ... on OTCQX®, the best marketplace for established U.S. ... Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO ... execution of its growth strategy and achievement of ...
(Date:8/21/2014)... 21, 2014 Gallus BioPharmaceuticals ... development and manufacturing organization (CMO) announced today that ... an oncology company focused on the development of ... manufacture the anti-prostate specific membrane antigen (PSMA) monoclonal ... Under the agreement the antibody will be ...
Breaking Biology Technology:Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 2Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 3Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 4His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 2His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 3OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3
... Jennerex, Inc., a private clinical-stage biotherapeutics company focused on ... products for cancer, today presented preliminary data from a ... with advanced liver cancer showing a benefit in overall ... from the study HEP007 indicated that the risk of ...
... 19, 2011 Metabolex, Inc., a biopharmaceutical company focused ... for the treatment of metabolic diseases, announced today that ... arhalofenate (MBX-102), its product candidate for the management of ... double-blind, placebo-controlled study will evaluate the safety and urate-lowering ...
... May 19, 2011 Reportlinker.com announces that ... in its catalogue: Global ... This report analyzes the ... The report provides separate comprehensive analytics for ...
Cached Biology Technology:Jennerex and Partners Present Positive JX-594 Randomized Phase 2 Clinical Data Showing Promising Survival Benefit in Patients with Advanced Liver Cancer 2Jennerex and Partners Present Positive JX-594 Randomized Phase 2 Clinical Data Showing Promising Survival Benefit in Patients with Advanced Liver Cancer 3Jennerex and Partners Present Positive JX-594 Randomized Phase 2 Clinical Data Showing Promising Survival Benefit in Patients with Advanced Liver Cancer 4Jennerex and Partners Present Positive JX-594 Randomized Phase 2 Clinical Data Showing Promising Survival Benefit in Patients with Advanced Liver Cancer 5Metabolex Initiates Phase 2 Trial of Arhalofenate 2Global Biosimilars Industry 2Global Biosimilars Industry 3Global Biosimilars Industry 4Global Biosimilars Industry 5Global Biosimilars Industry 6Global Biosimilars Industry 7Global Biosimilars Industry 8Global Biosimilars Industry 9Global Biosimilars Industry 10
(Date:8/22/2014)... and the bees. But that old expression leaves ... fertilization process for flowering plants is particularly complex ... female reproductive cells. New research from an international ... including Carnegie,s Wolf Frommer, David Ehrhardt, and Guido ... that guides flowering plant fertilization. It is published ...
(Date:8/21/2014)... unknown process for harvesting energy and producing oxygen from ... University scientist has discovered. The discovery lays the foundation ... energy from the Sun, and understanding dense blooms like ... worldwide. A paper describing the discovery will be published ... journal Science on 21 August 2014. , ...
(Date:8/21/2014)... Nine researchers from Beth Israel Deaconess Medical Center (BIDMC ... World,s Most Influential Scientific Minds 2014," a comprehensive ... a web resource for science metrics and research performance ... the most influential "are performing and publishing work that ... their science," according to a Thomson Reuters statement. Researchers ...
Breaking Biology News(10 mins):Calcium and reproduction go together 2Hot-spring bacteria reveal ability to use far-red light for photosynthesis 2Hot-spring bacteria reveal ability to use far-red light for photosynthesis 3BIDMC researchers named among 'the most influential scientific minds' 2BIDMC researchers named among 'the most influential scientific minds' 3
... people experience X-ray computed tomography (CT) scanners when they are evaluated ... of Dr. Quin Liu, PhD., in Wuhan China, rice plants were ... of an agriculture study to increase rice yield. Into the ... in an automated facility that could process 4,320 rice plants a ...
... Inspired by Mother Nature, scientists are reporting development of ... to survive in a dormant condition for long periods despite ... in Journal of the American Chemical Society , they ... that protect anthrax and certain other bacterial cells, making those ...
... known that landfills produce methane, but had a hard time ... as a friendly environment for the organisms that produce methane. ... species of microbe is paving the way for other methane ... called Methanosarcina barkeri appears to be the key ...
Cached Biology News:Seeing rice with X-rays may improve crop yields 2Researchers ID microbe responsible for methane from landfills 2